12:08 PM EST, 02/03/2025 (MT Newswires) -- UniQure ( QURE ) said Monday that it has completed enrollment in the first cohort of patients of the phase 1/2a trial of its gene therapy candidate, AMT-191, for the treatment of Fabry disease.

The firm also said the Independent Data Monitoring Committee recommended proceeding with enrollment in the second cohort after it found no significant safety concerns following a safety data review from the first cohort's initial two patients.

The company said it expects to initiate enrollment of second dose cohort in the first quarter of 2025.

Price: 15.47, Change: -0.27, Percent Change: -1.72